Outcome of conventional radiotherapy in small centrally located tumours or lymph nodes: minimal toxicity, remarkable survival but challenging loco-regional control

References

• Khalil AA, Hoffmann L, Moeller DS, et al. New dose constraint reduces radiation-induced fatal pneumonitis in locally advanced non-small cell lung cancer patients treated with intensity-modulated radiotherapy. Acta Oncol. 2015;54(9):1343–1349. doi:10.3109/0284186X.2015.1061216.
   PubMed Web of Science ®Google Scholar
• Bradley JD, Paulus R, Komaki R, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol. 2015;16(2):187–199. doi:10.1016/S1470-2045(14)71207-0.
   PubMed Web of Science ®Google Scholar
• van Diessen J, De Ruysscher D, Sonke J-J, et al. The acute and late toxicity results of a randomized phase II dose-escalation trial in non-small cell lung cancer (PET-boost trial). Radiother Oncol. 2019;131:166–173. doi:10.1016/j.radonc.2018.09.019.
   PubMed Web of Science ®Google Scholar
• Hansen O, Knap MM, Khalil A, et al. A randomized phase II trial of concurrent chemoradiation with two doses of radiotherapy, 60 gy and 66 gy, concomitant with a fixed dose of oral vinorelbine in locally advanced NSCLC. Radiother Oncol. 2017;123(2):276–281. doi:10.1016/j.radonc.2017.03.017.
   PubMed Web of Science ®Google Scholar
• De Ruysscher D, van Baardwijk A, Wanders R, et al. Individualized accelerated isotoxic concurrent chemoradiotherapy for stage III non-small cell lung cancer: 5-Year results of a prospective study. Radiother Oncol. 2019;135:141–146. doi:10.1016/j.radonc.2019.03.009.
   PubMed Web of Science ®Google Scholar
• Bradley JD, Hu C, Komaki RR, et al. Long-term results of NRG oncology RTOG 0617: standard- versus high-dose chemoradiotherapy with or without cetuximab for unresectable stage III non-small-cell lung cancer. J Clin Oncol. 2020;38(7):706–714. doi:10.1200/JCO.19.01162.
   PubMed Web of Science ®Google Scholar
• Antonia SJ, Villegas A, Daniel D, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med. 2018;379(24):2342–2350. doi:10.1056/NEJMoa1809697.
   PubMed Web of Science ®Google Scholar
• Møller DS, Lutz CM, Khalil AA, et al. Survival benefits for non-small cell lung cancer patients treated with adaptive radiotherapy. Radiother Oncol. 2022;168:234–240. doi:10.1016/j.radonc.2022.01.039.
   PubMed Web of Science ®Google Scholar
• Spigel DR, Faivre-Finn C, Gray JE, et al. Five-Year survival outcomes From the PACIFIC trial: durvalumab After chemoradiotherapy in stage III Non-Small-Cell lung cancer. J Clin Oncol. 2022;40(12):1301–1311. doi:10.1200/JCO.21.01308.
   PubMed Web of Science ®Google Scholar
• Klement RJ, Sonke JJ, Allgäuer M, et al. Correlating dose variables with local tumor control in stereotactic body radiation therapy for Early-Stage Non-Small cell lung cancer: a modeling study on 1500 individual treatments. Int J Radiat Oncol Biol Phys. 2020;107(3):579–586. doi:10.1016/j.ijrobp.2020.03.005.
   PubMed Web of Science ®Google Scholar
• Timmerman RD, Paulus R, Pass HI, et al. Stereotactic body radiation therapy for operable Early-Stage lung cancer: findings From the NRG oncology RTOG 0618 trial. JAMA Oncol. 2018;4(9):1263–1266. doi:10.1001/jamaoncol.2018.1251.
   PubMed Web of Science ®Google Scholar
• Fakiris AJ, McGarry RC, Yiannoutsos CT, et al. Stereotactic body radiation therapy for early-stage nonsmall-cell lung carcinoma: four-year results of a prospective phase II study. Int J Radiat Oncol Biol Phys. 2009;75(3):677–682. doi:10.1016/j.ijrobp.2008.11.042.
   PubMed Web of Science ®Google Scholar
• Hoyer M, Roed H, Hansen AT, et al. Prospective study on stereotactic radiotherapy of limited-stage non small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2006;66(4):S128–S135. doi:10.1016/j.ijrobp.2006.01.012.
   Web of Science ®Google Scholar
• Timmerman R, McGarry R, Yiannoutsos C, et al. Excessive toxicity when treating Central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol. 2006;24(30):4833–4839. 20doi:10.1200/JCO.2006.07.5937.
   PubMed Web of Science ®Google Scholar
• Lindberg K, Grozman V, Karlsson K, et al. The HILUS-trial - a prospective nordic multi-center phase II study of ultra-Central lung tumors treated with stereotactic body radiotherapy. J Thorac Oncol. 2021;16(7):1200–1210.
   PubMed Web of Science ®Google Scholar
• Rim CH, Shin IS, Yoon WS, et al. Dose-response relationship of stereotactic body radiotherapy for ultracentral tumor and comparison of efficacy with Central tumor: a meta-analysis. Transl Lung Cancer Res. 2020;9(4):1268–1284. doi:10.21037/tlcr-20-503.
   PubMed Web of Science ®Google Scholar
• Tekatli H, Duijm M, Oomen-de HE, et al. Normal tissue complication probability modeling of pulmonary toxicity After stereotactic and hypofractionated radiation therapy for Central lung tumors. Int J Radiat Oncol Biol Phys. 2018;100(3):738–747. doi:10.1016/j.ijrobp.2017.11.022.
   PubMed Web of Science ®Google Scholar
• Roach MC, Robinson CG, DeWees TA, et al. Stereotactic body radiation therapy for Central Early-Stage NSCLC: results of a prospective phase I/II trial. J Thorac Oncol. 2018;13(11):1727–1732. doi:10.1016/j.jtho.2018.07.017.
   PubMed Web of Science ®Google Scholar
• Baker R, Han G, Sarangkasiri S, et al. Clinical and dosimetric predictors of radiation pneumonitis in a large series of patients treated with stereotactic body radiation therapy to the lung. Int J Radiat Oncol Biol Phys. 2013;85(1):190–195. doi:10.1016/j.ijrobp.2012.03.041.
   PubMed Web of Science ®Google Scholar
• Nishimura S, Takeda A, Sanuki N, et al. Toxicities of organs at risk in the mediastinal and hilar regions following stereotactic body radiotherapy for centrally located lung tumors. J Thorac Oncol. 2014;9(9):1370–1376. doi:10.1097/JTO.0000000000000260.
   PubMed Web of Science ®Google Scholar
• Hoffmann L, Persson GF, Nygård L, et al. Thorough design and pre-trial quality assurance (QA) decrease dosimetric impact of delineation and dose planning variability in the STRICTLUNG and STARLUNG trials for stereotactic body radiotherapy (SBRT) of Central and ultra-Central lung tumours. Radiother Oncol. 2022;171:53–61. doi:10.1016/j.radonc.2022.04.005.
   PubMed Web of Science ®Google Scholar
• Sloth Møller D, Knap MM, Nyeng TB, et al. Difference in target definition using three different methods to include respiratory motion in radiotherapy of lung cancer. Acta Oncol. 2017;56(11):1604–1609. doi:10.1080/0284186X.2017.1373848.
   PubMed Web of Science ®Google Scholar
• Wolthaus JWH, Sonke J-J, van Herk M, et al. Comparison of different strategies to use four-dimensional computed tomography in treatment planning for lung cancer patients. Int J Radiat Oncol Biol Phys. 2008;70(4):1229–1238. doi:10.1016/j.ijrobp.2007.11.042.
   PubMed Web of Science ®Google Scholar
• Hoffmann L, Holt MI, Knap MM, et al. Anatomical landmarks accurately determine interfractional lymph node shifts during radiotherapy of lung cancer patients. Radiother Oncol. 2015;116(1):64–69. doi:10.1016/j.radonc.2015.06.009.
   PubMed Web of Science ®Google Scholar
• Møller DS, Holt MI, Alber M, et al. Adaptive radiotherapy for advanced lung cancer ensures target coverage and decreases lung dose. Radiother Oncol. 2016;121(1):32–38. doi:10.1016/j.radonc.2016.08.019.
   PubMed Web of Science ®Google Scholar
• Schytte T, Nielsen TB, Brink C, et al. Pattern of loco-regional failure after definitive radiotherapy for non-small cell lung cancer. Acta Oncol. 2014;53(3):336–341. doi:10.3109/0284186X.2013.868035.
   PubMed Web of Science ®Google Scholar
• Bradley JD, Ieumwananonthachai N, Purdy JA, et al. Gross tumor volume, critical prognostic factor in patients treated with three-dimensional conformal radiation therapy for non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys. 2002;52(1):49–57. doi:10.1016/s0360-3016(01)01772-2.
   PubMed Web of Science ®Google Scholar
• van Diessen JN, Chen C, van den Heuvel MM, et al. Differential analysis of local and regional failure in locally advanced non-small cell lung cancer patients treated with concurrent chemoradiotherapy. Radiother Oncol. 2016;118(3):447–452. doi:10.1016/j.radonc.2016.02.008.
   PubMed Web of Science ®Google Scholar
• Nygård L, Vogelius IR, Fischer BM, et al. A competing risk model of first failure site after definitive chemoradiation therapy for locally advanced Non-Small cell lung cancer. J Thorac Oncol. 2018;13(4):559–567. doi:10.1016/j.jtho.2017.12.011.
   PubMed Web of Science ®Google Scholar
• Brahme A. Dosimetric precision requirements in radiation therapy. Acta Radiol Oncol. 1984;23(5):379–391. doi:10.3109/02841868409136037.
   PubMed Web of Science ®Google Scholar
• Webb S, Nahum AE. A model for calculating tumour control probability in radiotherapy including the effects of inhomogeneous distributions of dose and clonogenic cell density. Phys Med Biol. 1993;38(6):653–666. doi:10.1088/0031-9155/38/6/001.
   PubMed Web of Science ®Google Scholar
• von Reibnitz D, Shaikh F, Wu AJ, et al. Stereotactic body radiation therapy (SBRT) improves local control and overall survival compared to conventionally fractionated radiation for stage I non-small cell lung cancer (NSCLC). Acta Oncol. 2018;57(11):1567–1573. doi:10.1080/0284186X.2018.1481292.
   PubMed Web of Science ®Google Scholar
• Haque W, Verma V, Polamraju P, et al. Stereotactic body radiation therapy versus conventionally fractionated radiation therapy for early stage non-small cell lung cancer. Radiother Oncol. 2018;129(2):264–269. doi:10.1016/j.radonc.2018.07.008.
   PubMed Web of Science ®Google Scholar
• Khalil AA, Knap MM, Møller DS, et al. Local control after stereotactic body radiotherapy of centrally located lung tumours. Acta Oncol. 2021;60(8):1069–1073. doi:10.1080/0284186X.2021.1914345.
   PubMed Web of Science ®Google Scholar
• Nyman J, Hallqvist A, Lund J, et al. SPACE- A randomized study of SBRT vs conventional fractionated radiotherapy in medically inoperable stage I NSCLC. Radiother Oncol. 2016;121(1):1–8. doi:10.1016/j.radonc.2016.08.015.
   PubMed Web of Science ®Google Scholar
• Belderbos JS, Heemsbergen WD, De JK, et al. Final results of a phase I/II dose escalation trial in non-small-cell lung cancer using three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys. 2006;66(1):126–134. doi:10.1016/j.ijrobp.2006.04.034.
   PubMed Web of Science ®Google Scholar
• Kong FM, Ten Haken RK, Schipper MJ, et al. High-dose radiation improved local tumor control and overall survival in patients with inoperable/unresectable non-small-cell lung cancer: long-term results of a radiation dose escalation study. Int J Radiat Oncol Biol Phys. 2005;63(2):324–333. doi:10.1016/j.ijrobp.2005.02.010.
   PubMed Web of Science ®Google Scholar
• Cooke SA, de Ruysscher D, Reymen B, et al. 18F-FDG-PET guided vs whole tumour radiotherapy dose escalation in patients with locally advanced non-small cell lung cancer (PET-Boost): results from a randomised clinical trial. Radiother Oncol. 2023;181:109492. doi:10.1016/j.radonc.2023.109492.
   PubMed Web of Science ®Google Scholar
• Møller DS, Nielsen TB, Brink C, et al. Heterogeneous FDG-guided dose-escalation for locally advanced NSCLC (the NARLAL2 trial): design and early dosimetric results of a randomized, multi-Centre phase-III study. Radiother Oncol. 2017;124(2):311–317. doi:10.1016/j.radonc.2017.06.022.
   PubMed Web of Science ®Google Scholar
• Punekar SR, Shum E, Grello CM, et al. Immunotherapy in non-small cell lung cancer: past, present, and future directions. Front Oncol. 2022;12:877594. doi:10.3389/fonc.2022.877594.
   PubMed Web of Science ®Google Scholar